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Alzheimer’s disease (AD) is the most common cause of dementia. Amyloid plaques and neuroﬁbrillary tangles are prominent
pathological features of AD. Aging and age-dependent oxidative stress are the major nongenetic risk factors for AD. The beta-
amyloid peptide (Aβ), the major component of plaques, and advanced glycation end products (AGEs) are key activators of
plaque-associated cellular dysfunction. Aβ and AGEs bind to the receptor for AGEs (RAGE), which transmits the signal from
RAGE via redox-sensitive pathways to nuclear factor kappa-B (NF-κB). RAGE-mediated signaling is an important contributor
to neurodegeneration in AD. We will summarize the current knowledge and ongoing studies on RAGE function in AD. We will
also present evidence for a novel pathway induced by RAGE in AD, which leads to the expression of thioredoxin interacting
protein (TXNIP), providing further evidence that pharmacological inhibition of RAGE will promote neuroprotection by blocking
neurovascular dysfunction in AD.
1.Introduction
Alzheimer’sdisease(AD)pathologyischaracterizedinbythe
presence of several kinds of amyloid plaques and neuroﬁb-
rillary tangles in the brain, which are mainly composed by
the beta amyloid (Aβ), derived from the proteolytic cleavage
of the amyloid precursor protein (APP), and hyperphos-
phorylated tau [1]. AD can be subdivided in 2 major forms:
(i) familial AD, which represents rare early onset forms due
to gene mutations leading to enhanced Aβ production or
faster aggregating Aβ peptide; (ii) sporadic AD forms, which
represent about 95% of AD cases [2]. The pathogenesis of
sporadic AD is extremely complex, and its ultimate cause
is still under debate. Epidemiological studies reveal growing
evidencethatmostcasesofsporadicADlikelyinvolveacom-
bination of genetic and environmental risk factors. However,
the only risk factors so far validated for late-onset disease are
age, family history, and the susceptibility gene ApoE4 allele
[3].
A hallmark of the aged brain is the presence of oxidative
stress [4]. Aβ ﬁbrils are toxic by generating oxygen free
radicals in the absence of any cellular element [5, 6].
However, synaptic dysfunction and behavioral changes in
AD precede the formation of large Aβ aggregates and ﬁbrils.
Indeed, Aβ dimers and soluble oligomers are considered the
major toxic form [7, 8], while ﬁbrils-induced oxidative stress
operates late in the course of AD. Thus, the mechanisms
through which Aβ exerts its toxic eﬀect at the early stages
of AD remain still to be clariﬁed. Recent evidences suggest
that age-relate cofactors play a key function in mediating the
toxicity of Aβ at early, AD stages. One of the risk factors
is diabetes mellitus (DM) and several studies demonstrated
a link between DM and AD [9–11]. In agreement, both
hyperglycemia in DM and age-dependent oxidative stress
induce the formation of advanced glycation end products
(AGEs) [12, 13]. AGEs derive from a multistep reaction of
reducing sugars or dicarbonyl compounds with the amino
groups of proteins [13]. AGEs accumulate in AD brain and2 International Journal of Alzheimer’s Disease
accelerate Aβ deposition [14, 15]. It has been shown that the
interaction of AGEs with their receptor (RAGE) induces the
productionofreactiveoxygenspecies(ROS),participatingto
theearlytoxiceventsthatleadtoADprogression[16].RAGE
is amultiligand receptoroftheimmunoglobulin superfamily
of cell surface molecules acting as counterreceptor for
various ligands, such as AGEs, S100/calgranulins, HMGB1
proteins,Aβ peptides,andthefamilyofbeta-sheetﬁbrils[17,
18]. Its ectodomain is constituted by one V-type followed by
two C-type domains. The N-terminal V-domain seems to be
implicated in the recognition of RAGE ligands [19]. Studies
with RAGE−/− mice conﬁrmed that RAGE contributes to
AD [20, 21]. Notably, diabetic AD patients show enhanced
cell damage, which is RAGE dependent [11]. Thus, RAGE
seems to represent an excellent cofactor promoting Aβ-
induced cellular dysfunction.
Several studies indicate that RAGE induces neurodegen-
eration in AD via multiple pathways. In AD brain, RAGE
is evident in neurons, microglia, astrocytes, and in brain
endothelial cells [19, 22]. The activation of RAGE expressed
in neuronal cells promotes synaptic dysfunction. RAGE also
promotes neurodegeneration by inducing inﬂammation in
glial cells. Moreover, RAGE is responsible of the transport of
Aβ from the blood to the brain [23], inducing cerebrovas-
cular dysfunction that ultimately results in neurovascular
inﬂammation and subsequent synaptotoxicity [24]. Notably,
the G82S RAGE allele (a polymorphism in RAGE sequence)
is associated with increased risk of AD [25], supporting the
hypothesis that RAGE is implicated in the progression of
sporadic AD. At early stages of AD, when the level of Aβ
and AGEs are low, RAGE ampliﬁes their eﬀects on diﬀerent
cell types, ultimately contributing to neuronal dysfunction
and neurodegeneration. Diﬀerent animal models have been
analyzed to decipher the role of RAGE in AD progression:
(i) injection of AGEs into the rat hippocampus; (ii) injection
of Aβ in rat hippocampus; (iii) various transgenic (Tg) mice
expressingoneormoregenevariantoftheamyloidprecursor
protein (APP); (iv) presenilins, which are implicated in
APP cleavage and Aβ production leading to amyloid plaque
formation; (v) tau that forms the characteristic tangles when
is hyperphosphorylated. In addition, the brain of animal
model of diabetes was analyzed to ﬁnd the link between DM
and AD.
We recently demonstrated that RAGE triggering induces
the expression of thioredoxin interacting protein (TXNIP)
in various cell types, promoting inﬂammation [26, 27].
TXNIP binds to thioredoxin (TRX) and inhibits its anti-
oxidant activity, leading to oxidative stress in various cell
type [28]. We demonstrated that oxidative stress plays a key
function in AD progression [6, 29]. TXNIP expression is
enhanced in several disease risk for AD: diabetes [26, 28, 30],
hypertension [31], and ischemia [32]. Insulin is necessary
to maintain normal brain function, and peripheral insulin
resistance enhances the risk to develop AD, by aﬀecting brain
glucose metabolism, neurotransmitters levels, enhancing
inﬂammation [33]. Interestingly, TXNIP is necessary to
mediate insulin resistance in diabetes [34]. TXNIP is early
overexpressed in the hippocampus of an AD mice model.
Moreover, Aβ induces the RAGE-dependent expression of
T X N I Pi na ni nv i t r om o d e lo ft h eb l o o db r a i nb a r r i e r
(BBB).
Notably, TXNIP and RAGE, both may exacerbate injury
and inﬂammation when chronically activated, while they
mediate neuronal repair when transiently expressed [26, 27].
Moreover, RAGE can also promote neurite outgrowth [35].
Thus, inhibition of chronic activation of RAGE and TXNIP
can eﬃciently provide neuroprotection in AD.
2. Role of RAGE in Amplifying Age-Dependent
Oxidative Stress
Human aging is an inexorable biological phenomenon
characterized by a progressive decrease in physiological
capacity,andthereducedabilitytorespondtoenvironmental
stresses leads to increased susceptibility to disease. In 1956,
Harman developed the free radical theory of aging [36]
that argues that aging results from the damage generated
by reactive oxygen species (ROS) [37]. According to this
theory, aging is the result of accumulation of oxidative-
damaged macromolecules (lipid, protein, DNA) due to the
aerobic metabolism, which accumulate throughout lifetime
[38]. Thus, aging is associated with imbalance between the
rate of antioxidant defenses and intracellular concentration
of ROS. The relevance role of ROS in aging consists in their
ability to attack vital cell components like polyunsaturated
fatty acids, proteins, and nucleic acids. These reactions
can alter intrinsic membrane properties like ﬂuidity, ion
transport, loss of enzyme activity, protein cross-linking, and
inhibition of protein synthesis, DNA damage, ultimately
resulting in cell death. Many disorders, like cardiovascular
diseases, rheumatoid arthritis, cancer, atherosclerosis, and
AIDS, have been reported as the ROS-mediated disorders.
ROS has been also implicated in neurodegenerative
diseaseslikeParkinsonandAlzheimerdiseases(AD).Indeed,
the brain is particularly vulnerable to oxidative damage
because of its high utilization of oxygen, increased levels
of polyunsaturated fatty acid, and relatively high levels of
redox transition metal ions; in addition, the brain has
relatively low levels of antioxidants [39]. The presence
of iron ion in an oxygen-rich environment can further
lead to enhanced production of hydroxyl free radicals and
ultimately lead to a cascade of oxidative events [6]. In
the AD brain, the role of ROS has been well documented
with markers for protein, DNA, RNA oxidation, and lipid
peroxidation. In fact, increased reactive carbonyls were the
ﬁrst form of oxidative damage identiﬁed in AD [40]. Several
studies showed the presence of additional protein markers
like protein nitration supporting that nitrosative stress also
contributes to neurodegeneration disease [39]. Ampliﬁed
lipid peroxidation has been also described in several neu-
rodegenerative diseases [41]. AD brains show an increase
in free 4-hydroxy-2-trans-nonenal (HNE) in amygdala,
parahippocampal gyrus, and hippocampus of the AD brain
comparedwithage-matchedcontrols[42].Inaddition,DNA
is a target of ROS, which leads to cellular aging. Oxidative
damagetoDNAinducesstrandbreaksDNA-DNAandDNA-
protein cross-linking and translocation. DNA bases are also
attacked by the lipid peroxidation. This modiﬁcation canInternational Journal of Alzheimer’s Disease 3
cause inappropriate base leading to alter protein synthesis
[43]. AGEs are considered important markers of oxidative
stress and accumulating during aging and diseases, markers
of carbonyl stress, which accumulate due to an increased
level of sugars and reactive dicarbonyl compounds such
as glucose, fructose, deoxyglucose, glyoxal, methylglyoxal,
and triosephosphates [38, 44]. AGE formation begins when
amino groups of proteins particularly the N-terminal amino
group and side chains of lysine and arginine react nonen-
zymatically with these reactive carbonyl compounds [45].
This posttranslational modiﬁcation, termed “non-enzymatic
glycation” or “glycation,” derives from reversible Schiﬀ-base
adducts to protein through oxidations and dehydrations
bound Amadori products. The irreversible formation of
AGEs results in protease-resistant cross-linking of peptides,
proteins, and other macromolecules. AGEs are localized in
pyramidal neurons that appear to selectively accumulate
AGEs in an age-dependant manner. In the AD brain,
AGE colocalize with activated astrocytes [46]. In 2011,
Srikanth et al. showed that the percentage of AGE posi-
tive neurons and astroglia increase in Alzheimer with the
progression of disease, which might contribute to many
aspects of neuronal dysfunction in AD by processes, such as
inﬂammatory activation of microglia, or direct cytotoxicity
via formation of free radicals [45], presumably mediated
through activation of their receptor RAGE [45]. RAGE
binds also the monomeric and ﬁbrillary forms of Aβ.
Upon binding of ligands (AGEs and Aβ), RAGE triggers
intracellular signaling pathways via phosphatidylinositol-
3 kinase, Ki-Ras, and mitogen-activated protein kinases,
the Erk1 and Erk2 [17]. Those pathways culminate in the
activation of the transcription factor nuclear factor kappa
B( N F - κB) and subsequent transcription of a number of
genes, including endothelin-1, tissue factor, interleukin (IL)-
1, IL-6, and tumor necrosis factor (TNF)-α [17, 18, 47].
Activation of NF-κB and induction of cytokines can also
contribute to neuronal plasticity and the cellular response
to neurodegeneration [48]. RAGE-induced signaling results
in an initial neuroprotective eﬀect [27], while it contributes
to cellular dysfunction when chronically activated [17].
Notably, NF-κB induces the expression of RAGE, leading
to a positive loop, which amplify the cellular response
to external stress [17]. Furthermore, the engagement of
RAGE by AGEs triggers the generation of ROS via the
activation of NADPH oxidase (NOX) [45]. NOX catalyzes
the reduction of molecular O2 by donating an electron from
reduced nicotinamide adenine dinucleotide phosphate to
generate superoxide. NOX plays an important role in AD-
induced ROS release. Thus, RAGE can be considered a key
mediator of age-induced oxidative stress by its capability to
amplify a stress signal, contributing to the progression of
neurodegenerative processes in sporadic AD.
3. Role of Neuronal RAGEin AD
T h ee x p r e s s i o nl e v e lo fR A G Ei sh i g hi nr o d e n tc o r t i c a l
neurons during the neonatal period [49], while its presence
strongly decreases during maturity with few cortical neurons
showing RAGE staining [50]. However, increased RAGE
expression in the brain parallels the progression of neurode-
generative diseases such as AD and Huntington’s disease [11,
21, 50, 51]. Notably, AD patients show enhanced RAGE, Aβ,
and AGEs expression in the whole hippocampus, especially
in dentate gyrus neurons and in CA3 pyramidal neurons,
which parallels the impairment of short-term memory that
is characteristic of AD due to neuronal dysfunction in the
hippocampus [11].
Chronic activation of RAGE aﬀects neuronal function by
activating various signaling pathways, promoting both the
phosphorylation of tau and the production of Aβ,a sw e l la s
it mediates Aβ toxicity.
Ar e c e n ts t u d yd e m o n s t r a t e st h a ti n j e c t i o no fA G E s
in the rat hippocampus leads to RAGE-dependent tau
hyperphosphorylation, spatial memory deﬁcit, and impaired
synaptictransmissionasdemonstratedbyinhibitionoflong-
term potentiation (LTP) in AGEs treated rats [52]. Altered
synaptic transmission correlated with RAGE-dependent tau
hyperphosphorylation that is due to inhibition of Akt and
subsequent activation of GSK3. RAGE activation leads also
to alterations of the postsynaptic machinery and decreased
density of dendritic spines [52]. Interestingly, AD is also
characterized by nonenzymatically glycated tau [53], which
induces neuronal oxidative and subsequent release of Aβ,
further supporting the role of metabolic dysfunction in
sporadic AD.
RAGE induces the expression of BACE 1, a key enzyme
implicated in the production of Aβ after stimulation with
either AGEs or Aβ. RAGE triggering leads to NF-κBn u c l e a r
translocation, which in turn enhances the expression of
RAGEleadingtoaviciouscircleproducingRAGE-dependent
cellular dysfunction [17, 18, 47]. In the brain of a rat model
of diabetes, activation of RAGE with AGEs leads to NF-κB-
dependent expression of BACE1 [16]. AGEs are increased
in the brain of AD patients [16]. These results conﬁrm
the role of AGEs and RAGE as molecules linking DM and
AD. Another study demonstrated that RAGE induces BACE1
expression in an AD mice model and in Aβ-stimulated
neuronal cells in vitro, by stimulating intracellular calcium
and activating nuclear factor of activated T cell 1 (NFAT)
[54].AlthoughthesignalingpathwayinducedbyRAGEupon
Aβ stimulation diﬀers compared to the study describing the
role of AGEs-stimulated RAGE in the DM animal model,
both reports underline the role of RAGE in promoting the
expression of BACE1, which enhances Aβ production in the
brain.
Several evidences clearly demonstrate that RAGE
strongly enhances Aβ-induced neuronal dysfunction in
AD transgenic (Tg) mice that overexpress a mutant form
of human amyloid precursor protein (mAPP), which
enhances the production of Aβ1-42 in neuronal cells. These
mice show Aβ-induced synaptotoxicity in the absence of
amyloid plaque [55]. Overexpression of RAGE anticipates
the onset of neuronal dysfunction in double transgenic
mice overexpressing neuronal mAPP and RAGE (Tg
mAPP/RAGE) compared to the single Tg expressing mAPP
only [56]. RAGE-dependent anticipation of neuronal
dysfunction was demonstrated by earlier impairment of
learning/memory in double Tgs mAPP/RAGE compared to4 International Journal of Alzheimer’s Disease
single Tg mAPP mice. Exacerbation of memory impairment
correlates with an anticipation of synaptic dysfunction
in the hippocampus of double Tgs as demonstrated by
alteration of LTP [56]. A decrement of cholinergic ﬁbers
and presynaptic terminals appears earlier in mAPP/RAGE
compared to map mice [56]. On the contrary, inhibition
of RAGE confers a neuroprotective eﬀect in AD mice, as
demonstrated in double Tg mice expressing mAPP and a
dominant negative form of RAGE (DNRAGE) in neurons
[56]. DNRAGE encodes for a truncated form of RAGE
lacking the intracellular domain necessary to induce RAGE-
mediated signaling, while maintaining the extracellular
domain for ligand binding. DNRAGE expression blocks
the function of endogenous RAGE [56]. Double Tg
mAPP/DNRAGE performed better in learning and memory
test compared to single Tg mAPP. Expression of DNRAGE
completely prevented neuropathologic changes such as loss
of cholinergic ﬁbers induced by mAPP [56].
Another area of the brain that is important in memory
process and is early aﬀe c t e di nA Di st h ee n t o r h i n a lc o r t e x .
In agreement, oligomeric Aβ1-42 impairs LTP in slides
derived from this brain area of wild-type (wt) mice [57].
Aβ-induced LTP alteration is inhibited by coaddition of anti-
RAGE IgG. Similarly, Aβ has not any eﬀect on slides derived
from RAGE null mice or Tg mice expressing neuronal
DNRAGE [57]. Moreover, this study demonstrated that
RAGE is implicated in Aβ-induced synaptic dysfunction
by activating the pathway of p38 MAPK [57, 58]. RAGE
plays a key role also in Aβ-dependent inhibition of synaptic
plasticity in intracortical circuits of the visual cortex, and
RAGE blockade confers a neuroprotective eﬀect against Aβ-
induced neuronal dysfunction [59]. In contrast, in Arc/swe
AD mice, which overexpress hAPP carrying the Swedish
(swe) mutation, which enhances Aβ production, and the
arctic (arc) mutation in Aβ sequence, which leads to a
faster aggregation of Aβ [60], the knockout of RAGE has
only a minimal eﬀect on Aβ load and does not ameliorate
synaptic dysfunction. Taken together, these data underline
the diﬀerences in the pathologic mechanisms implicated in
sporadic and familial AD, supporting the hypothesis that
RAGE plays a key function speciﬁcally in the progression of
sporadic AD.
S e v e r a ls t u d i e sd e m o n s t r a t e dt h a tA β and AGEs aﬀect
energy metabolism by decreasing mitochondrial activity
and induce neurodegeneration by producing mitochondrial
damage [19, 61]. Injection of Aβ25-35 toxic fragment in
rat CA1 hippocampus enhances RAGE expression in CA1,
which parallels with a 56% decrement in mitochondrial
activity and the presence of neurodegenerative events [62].
RAGE is involved in the uptake of Aβ and Aβ targeting to
mitochondria in cortical neurons, leading to a decrement in
the activity of a key mitochondrial respiratory enzyme, the
cytochrome c oxidase (COX IV) [63]. Blockade of RAGE
with anti-RAGE IgG or Aβ treatment of neurons derived
from RAGE null mice diminishes Aβ targeting to mitochon-
dria and subsequent mitochondrial dysfunction. Inhibition
ofRAGE-dependentp38MAKactivationblocksAβtargeting
to mitochondria and the subsequent mitochondrial damage.
RAGEcolocalizeswithAβinanintracellularcompartmentin
vivoinpyramidalcellsoftheCA3regionofthehippocampus
in the Tg mAPP mice [63] further supporting the role of
RAGE in Aβ-mediated neurodegeneration by aﬀecting mito-
chondrialfunction.Moreover,thesestudiesdemonstratethat
RAGE inhibition confers a neuroprotective eﬀect against Aβ-
mediated toxicity.
Several studies demonstrated that RAGE triggering
induces neurite outgrowth and neuronal diﬀerentiation [35,
64–69]. Furthermore, various studies including our own
demonstrate that RAGE is required for the repair of the
injured nerve [27, 70, 71]. Thus, RAGE plays a dual function:
it can mediate neurite outgrowth and neuronal repair,
while it induces neuronal dysfunction when chronically
activated.BecauseofthedualfunctionofRAGE,compounds
capable to block the chronic activation of RAGE can exert a
neuroprotective eﬀect in AD.
4. Role of RAGEinGlialCellsand
Inﬂammation in AD
Several evidences substantiate the association between neu-
roinﬂammatory mechanisms and the pathological events
leading to neuronal dysfunction and neurodegeneration.
The brain of AD patients shows chronic inﬂammation that
is characterized by the presence of reactive astrocytes and
activated microglia [72]. In healthy physiological conditions,
astrocytes are necessary to maintain brain homeostasis and
neuronal function. They provide metabolic support for neu-
rons in form of lactate, glutamate uptake and its conversion
into glutamine, and synthesis of antioxidant enzymes [72].
Microglial cells represent the innate immune system in the
brain as they can have a role as cerebral macrophages as
well they recruit and stimulate astrocytes [73]. Neuroin-
ﬂammation and microglial activations regulate the delicate
balance of immune response and neuronal homeostasis.
The innate immune responses of glial to injurious insults
or activating stimuli lead to beneﬁcial outcomes, such as
phagocytosis of pathogens, and production of reparative
and protective factors. However, chronic activation of glial
cells results in overproduction of proinﬂammatory factors,
disturb homeostasis, and ultimately exacerbates neuronal
dysfunction enhancing the progression of neuropathology
[74]. Activated astrocytes in AD fails in providing metabolic
support to neurons, contributing in inducing neurodegen-
eration [72]. Moreover, the activation of astrocytes and
microglia leads to chronic oxidative stress in AD patients,
further contributing to neurodegenerative processes [72].
Noteworthy, oxidative stress leads to the formation of AGEs,
which will activate RAGE [72]. Several studies including
our own demonstrated that activation of RAGE induces
oxidative stress and inﬂammation [18, 26, 27, 47, 75, 76].
Thus, glial inﬂammation and subsequent AGEs formation
in the presence of Aβ lead to a positive feedback loops
by which inﬂammation in AD increases proinﬂammatory
signaling. Inﬂammation enhances the processing of APP in
astrocytes by inducing BACE1 expression, leading to Aβ
deposition, further activating RAGE [45]. Moreover, RAGE
ligands enhance the expression of RAGE itself, leading of
a positive loop that induces the expression of RAGE andInternational Journal of Alzheimer’s Disease 5
subsequent oxidative stress and inﬂammation, which in turn
sustain the formation of AGEs and Aβ [17]. Interaction of
Aβ withRAGEresultsinincreasedexpressionofmacrophage
colony stimulating factor (M-CSF) in neuronal cells [77].
Stimulation of microglia by M-CSF results in enhanced
cell survival in cell stress conditions, proliferation and
induction of proinﬂammatory gene expression, which leads
to chronic inﬂammation and contributes to neurodegener-
ative processes [77]. Indeed, M-CSF induces cell survival
in microglial cells, which express c-fms receptor. On the
contrary, neuronal cells do not express c-fms receptor and
d on o tb e n e ﬁ to fM - C S Fp r o s u r v i v a le ﬀects, while they are
further aﬀected by the proinﬂammatory reaction of glial
cells [19]. The combination of AGEs and Aβ synergistically
induces the expression of proinﬂammatory cytokines, such
as TNF-α, IL-6, and M-CSF [45]. Moreover, Aβ induces the
expression and secretion of IL-1β in glial cells [45]v i aR A G E
[27]. RAGE is overexpressed in the microglial cell in AD
patients [78] and in an AD mice model (mAPP Tg) [56].
Activated microglia exacerbate Aβ-induced neuronal toxicity
[74], and RAGE is a key mediator of activated microglial
eﬀects in AD neuronal dysfunction [78, 79]. Targeted
overexpression of RAGE in the microglia of mAPP Tg mice
(double Tg mAPP/micRAGE) enhances the expression of
proinﬂammatory cytokines, increases Aβ production, and
accelerates neuropathologic changes compared to single
Tg mAPP, as demonstrated by anticipation of cholinergic
ﬁber loss and alteration in learning and memory [78].
Conversely, targeted overexpression of a dominant negative
form of RAGE in microglia of mAPP Tg mice (double
Tg mAPP/micDNRAGE) leads to a decrement of cytokines
and Aβ production and ameliorates neuronal dysfunction
compared to the single Tg mAPP [78]. In addition, targeted
overexpression of a dominant negative form of RAGE in
microglia (double Tg mAPP/micDNRAGE) attenuates Aβ-
induced synaptic dysfunction and Aβ-dependent inhibition
of long-term depression (LTD) in entorhinal cortex [79],
demonstrating that RAGE blockade inhibits Aβ-induced
neuronal dysfunction.
In summary, several studies support the hypothesis that
RAGE-mediated inﬂammation in AD contributes in induc-
ing neuronal dysfunction. On the contrary, these studies
demonstrate that inhibition of RAGE activation induces
neuroprotection and ameliorates AD progression.
5. RoleofRAGEandVascularDysfunctioninAD
The potential link between cerebral blood vessel disease
and Alzheimer’s is one promising area of research. Vascular
disease in the aged appears to have strong implications for
neurodegeneration leading to dementia. Preliminary studies
indicate that a broad spectrum of cerebrovascular lesions
could lead to a decline in cognitive function. Moreover,
nearly 80 percent of individuals with AD also have car-
diovascular disease at autopsy, supporting the hypothesis
that systemic vascular factors are risk factors for developing
AD. This risk encompasses diﬀerent forms of cardiovascular
disease,includingcoronaryarterydisease,carotidatheroscle-
rosis, history of hypertension or high cholesterol, type II
diabetes,andstrokeortransientischemicattacks[3].Indeed,
another hypothesis accounting for the pathogenesis of AD
is the impairment of the blood brain barrier (BBB) [23].
Cerebral blood vessels undergo profound changes with aging
and in AD [80]. The BBB blocks the free diﬀusion of
circulating molecules, leukocytes, and monocytes into the
brain interstitial space. Moreover, the BBB plays a key role
in regulating the glial and neuronal environment. The BBB
is constituted by endothelial cells fused by high-resistance
tightjunctions,inordertoseparatethebloodfromthebrain.
The disruption of the tight junctions aﬀects the regulated
transport of molecules and monocytes between blood and
brain and brain and blood and induces angiogenesis and
vessels regression, as well as brain hypoperfusion and
inﬂammation, promoting ultimately synaptic dysfunction
and neurodegeneration. Alterations of the BBB, vascular
density, fragmentation of vessels, alteration of the basement
membranes, and a decrement of mitochondria in the BBB
occur in AD [80]. Notably, BBB dysfunction is associated to
several risk factors for AD, such as stroke, cerebrovascular
ischemia, hypertension, and mutation in the ApoE gene,
which represents the only validated genetic risk factor of
AD [3]. Since the large majority of AD cases are sporadic,
it has been recently hypothesized that the accumulation of
Aβ into the brain and around blood vessels is due in an
alteration of clearance of Aβ from the brain and an enhanced
transport of Aβ into the brain [22]. In agreement, Tg2576
AD mice display enhanced BBB permeability compared to
control mice at 4 months of age, before the appearance
of plaque deposition and memory impairment [81]. A
correlation between BBB dysfunction and AD has been
demonstrated in AD patients. Noteworthy, BBB impairment
in these patients was not associated with vascular diseases
risk for AD, suggesting that the mechanisms inducing BBB
alterations in AD diﬀer from that one implicated in vascular
dementia [82].
RAGE is upregulated in AD brain vasculature [10, 11,
50]. In vivo studies show a RAGE-dependent transport
of Aβ1-40 and Aβ1-42 into the hippocampus and cortex,
which is inhibited by anti-RAGE blocking antibodies. The
transport of Aβ is strongly impaired and undetectable in
RAGE null mice [23]. RAGE-mediated transport of Aβ
leads to neurovascular stress, induction of the expression of
TNF-α and IL-6, which are detected mostly at the level of
neurons. Notably, infusion with physiological concentration
of Aβ (50pM) does not induce the expression of proin-
ﬂammatory cytokines, while neurovascular inﬂammation is
detected when pathological concentrations of Aβ (4.5nM)
areinfusedinthemice[23].Moreover,Aβ-RAGEinteraction
on the BBB induces vasoconstriction by promoting the
expression of endothelin-1. Notably, infusion of anti-RAGE
IgG ameliorates vascular dysfunction and blocks endothelin-
1 expression in Tg2576 AD mice [23].
It has been demonstrated that blood or BM-derived
monocytes inﬁltrate the AD brain, enhancing inﬂamma-
tion [83]. Antibodies against RAGE inhibit Aβ-induced
monocytes transmigration across the BBB [84], further
demonstrating the key role of RAGE in promoting neurovas-
cular inﬂammation in AD. Thus, RAGE expressed in brain6 International Journal of Alzheimer’s Disease
microvessels participates in AD by enhancing Aβ-transport
across the BBB and promoting neurovascular inﬂammation.
Conversely, inhibition of RAGE is beneﬁcial by blocking Aβ
transport across the BBB and the subsequent inﬂammatory
response.
6. RAGE-TXNIP Axis:Evidenceof a Novel
PathwayInduced byRAGEinAD
Recent studies using the human brain indicate that insulin
signaling is impaired in the AD brain. In neurons, this
insulin signaling plays a key role in modulating synaptic
function and neuronal senescence [85]. Spatial learning
in rats induces the expression of insulin receptor and of
insulin receptor substrate 1 (IRS 1) in the hippocampus.
Moreover, insulin regulates tau phosphorylation, a hallmark
of AD [86]. Insulin also regulates glucose metabolism in the
brain by modulating the expression of glucose transporters
[85]. TXNIP is an intriguing candidate molecule that may
provide a common link between brain insulin resistance
and AD. TXNIP was initially characterized for its capability
to inhibit thioredoxin, leading to oxidative stress [26, 87].
However, recent studies demonstrated that TXNIP regulates
glucose metabolism [88, 89], and its expression is associated
to the senescence process [90]. Notably, TXNIP null mice
are resistant to diabetes, showing that TXNIP is necessary
for the induction of insulin resistance [34]. In the mice
brain, TXNIP is expressed in the nuclei of astrocytes and
at low level in some neurons. TXNIP expression is low
in the hippocampus, while it is expressed constitutively in
hypothalamic neurons where it senses nutrients excess [91,
92]. TXNIP is also an early induced gene by apoptosis in
cerebellar neurons [93]. Insulin modulates memory by pro-
moting the expression of N-methyl-D-aspartate (NMDA)
receptors, which enhances neuronal Ca2+ inﬂux, consoli-
dating neuronal synaptic association and promoting LTP
[85]. Synaptic activity inhibits TXNIP expression in neurons
through NMDA receptor (NMDAR) activation. Blockade of
NMDAR enhances TXNIP expression, promoting neuronal
vulnerability to oxidative damage [94]. Notably, Aβ aﬀects
NMDAR function and traﬃcking [95], further supporting
the hypothesis that TXNIP may be implicated in AD.
However, no any study up to now investigated TXNIP
expressioninAD.Forthisreason,weanalyzedtheexpression
of TXNIP in the brain of the 5xFAD mice model of AD.
5xFAD expresses neuronal human APP carrying three AD
familiar mutation (Swedish, Florida, London) and presenilin
1 (PS1) containing 2 mutations (M146L and L286V) [96].
Since TXNIP is implicated in senescence, we used the 5xFAD
mice that display an early AD phenotype. Indeed, 5xFAD
mice show intraneuronal Aβ accumulation at 2 months age,
impaired learning/memory and reduction of synaptophysin
levels at 4 months age, and cortical neuronal apoptosis at
9 months age [96]. TXNIP was overexpressed in the hip-
pocampus (Figure 1 top and middle) and in the entherinal
cortex (not shown) of 5xFAD mice at 6 months of age
compared to control mice. To investigate TXNIP expression,
we used a mouse anti-TXNIP monoclonal antibody (clone
JY2, MBL). Similar results were obtained using a rabbit
anti-TXNIP polyclonal antibody (Invitrogen). TXNIP over-
expression paralleled enhanced astrogliosis, as demonstrated
by increased expression of glial ﬁbrillary acidic protein
in the hippocampus (Figure 1 bottom). The expression of
TXNIP in 5xFAD brain capillary endothelial cells in the
hippocampus was detected using both monoclonal and the
polyclonal anti-TXNIP antibodies (not shown). Noteworthy,
hippocampus and entorhinal cortex are associated to the
early learning/memory impairment in AD. Since we previ-
ously demonstrated that RAGE induces TXNIP expression
in retinal endothelial cells leading to chronic inﬂammation
andultimatelyinducingneurodegenerationindiabeticretina
[26, 30], we studied whether Aβ induces TXNIP expression
in brain derived endothelial cells (RBE4). RBE4 cells were
maintained in diﬀerentiation medium (F10/MEM, 2.5%
FCS, hydrocortisone 14μM, Hepes 10mM, bFGF 1μg/mL)
[97] for 5 days, before stimulated for 6h with Aβb1-42
(3μM). Since hyperglycemia (HG) induces TXNIP expres-
sion [26, 87], as control we stimulated RBE4 cells for
6h with HG (25mM glucose). Both HG and Aβ induced
TXNIP expression in RBE4 cells (Figure 2(a)). Aβ-induced
TXNIP expression was RAGE-dependent, because an anti-
RAGE blocking antibody (R&D system) [98]c o m p l e t e l y
inhibited Aβ-induced TXNIP expression in RBE4 cells
(Figure 2(b)). Moreover, RBE4 cells treated for 6h with
either HG (25mM) or Aβ (3μM) displayed enhanced RAGE
expression compared to control cells (Figure 2(c)). It has
been recently shown that TXNIP translocation to the plasma
membrane in endothelial cells participates in cell migration
leading to angiogenesis [99]. Since angiogenesis occurs in
AD [80], we investigated whether Aβ treatment induces
TXNIP translocation in RBE4 cells. Fractionation analysis of
cell extracts reveals that 45min of Aβ treatment increases
the cofractionation of TXNIP with the plasma membrane
markerVE-cadherin(Figure 3(a)).Thisresultwasconﬁrmed
by immunoﬂuorescence analysis of TXNIP subcellular local-
ization in the absence or presence of Aβ treatment, which
displays an enhanced colocalization of TXNIP with VE-
cadherin following Aβ treatment (Figure 3(b)). We also
observed an enhanced cofractionation of TXNIP with the
cytoskeletal fraction following Aβ treatment (Figure 3(a)),
which is conﬁrmed by immunoﬂuorescence analysis show-
ing enhanced colocalization of TXNIP with actin fol-
lowing Aβ treatment (data not shown). Notably, it has
been recently demonstrated that triggering of RAGE in
endothelial cells leads to altered actin reorganization and
membrane resealing, participating in vascular dysfunction
[100].
These data strongly imply that RAGE-TXNIP axis con-
tributes to vascular dysfunction in AD, suggesting that
RAGE-TXNIP axis is a novel therapeutic target to ameliorate
AD.
7. Pharmacological Treatmentto Ameliorate
AD Progressionby Blocking RAGE
S inc eRA GEisimplicat edinADpr ogr essionb yor c hestrating
cellular dysfunction in various cell types, a pharmacological
treatment aimed to inhibit RAGE chronic activation wouldInternational Journal of Alzheimer’s Disease 7
Control 5xFAD
Figure 1: TXNIP is overexpressed in the hippocampus of the 5xFAD mice. Top: Floating brain slices were incubated 24h with mouse anti-
TXNIP monoclonal antibody in PBS 3% BSA, 0.1% Triton X-100 (blocking) at 4◦C. Slides were washed 3 times for 15min with PBS and
incubated for 45min with TRITC-conjugated secondary antibody (red). Nuclei were stained by incubating the slides with Hoecst (blue)
together with the secondary antibody. Slides were mounted using mounting medium and analyzed with confocal microscopy (Zeiss).
Center: Confocal analysis and 3 dimensional reconstruction (Zen software of Zeiss) of TXNIP staining in the hippocampus. Bottom:
Floating brain slices were incubated 2h at room temperature with rabbit anti-GFAP polyclonal antibody in PBS 3% BSA, 0.1% Triton
X-100 (blocking). Slides were washed 3 times for 15min with PBS and incubated for 45min with FITC-conjugated secondary antibody
(green). Slides were mounted using mounting medium and analyzed with confocal microscopy (Zeiss). These results are representative of 4
independent experiments (4 animals).
be beneﬁcial in ameliorating AD. The small molecule PF-
04494700 inhibits RAGE by blocking the interaction of the
receptor with its ligands such as Aβ, AGEs, HMGB1, and
members of the proinﬂammatory S100 family members
[101]. Thus, PF-04494700 was thought to be capable to ame-
liorate AD by inhibiting both inﬂammation and Aβ-induced
neurodegeneration. An initial 10-week-long phase 2 safety
trial demonstrated a good safety proﬁle of PF-04494700 in
AD patients, even if there was not signiﬁcant clinical ame-
lioration during the short observation period [101]. Thus,
a long-term clinical trail was initiated with three group of
treatment:onegroupreceivedplacebo,thesecond20mg/day
of PF-04494700, and the third 5mg/day of the drug, and
the researcher analyzed Alzheimer’s Disease Assessment-
cognitive subscale (ADAS-cog) score, safety indicators, addi-
tional cognitive tests, structural magnetic resonance imaging
(MRI) measurements, Aβ imaging by positron emission
tomography (PET), and levels of the biomarkers Aβ and
tau in cerebrospinal ﬂuid (CSF). However, the trial was
discontinued after 12 months because the highest dose of
PF-04494700 resulted in worsening the ADAS-cog score and
side eﬀects, while the lower dose was safe (see Alzheimer
Research Forum article: “Door Slams on RAGE” 9th Novem-
ber 2011 http://www.alzforum.org/new/detail.asp?id=2960).
Therefore, the use of this drug to ameliorate AD is still
debatable. Although the clinical trial was abandoned, the
researchers continued to follow the patients and they col-
lected data obtained from visiting these patients after 18
months from the start of the trial. When Douglas Galasko
presentedthecompleteddatasetduringthe4thInternational
ConferenceonClinicalTrialsonAlzheimer’sDisease(CTAD;
November 3–5, 2011, in San Diego, CA, USA), he notably8 International Journal of Alzheimer’s Disease
HG −−
− −
+
+
Actin
TXNIP
Aβ
(a)
−
−−
++
+
Actin
TXNIP
Aβ
Anti-RAGE blocking
(b)
− −
− −
+
+
Actin
Aβ
HG
RAGE
(c)
Figure 2: Aβ induces RAGE-dependent TXNIP expression in RBE4 brain endothelial cells. RBE4 cells were maintained 5 days in
diﬀerentiation medium (F10/MEM, 2.5% FCS, hydrocortisone 14μM, Hepes 10mM, bFGF 1μg/mL). RBE4 cells were stimulated for 6h
with either Aβ1-42 (3μM) or HG (25mM) in diﬀerentiation medium. Cells were lysed in RIPA buﬀer. TXNIP expression was analyzed by
western blotting using a mouse anti-TXNIP monoclonal antibody (MBL). Protein loading was analyzed by western blotting of actin. (b)
RBE4 cells were maintained as described in (a) and stimulated for 6h with either Aβ1-42 (3μM) both in the absence or presence of an
anti-RAGE blocking antibody (R&D system). TXNIP expression and protein loading were analyzed by western blotting as in (a). (c) RBE4
cells were maintained as described in (a) and stimulated for 6h with either Aβ1-42 (3μM) or HG (25mM) in diﬀerentiation medium. RAGE
expression was analyzed by western blotting using a rabbit anti-RAGE polyclonal antibody (Santa Cruz). Protein loading was analyzed by
western blotting of actin. These data are representative of 3 independent experiments.
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Figure 3: Aβ enhances TXNIP translocation to the plasma membrane. (a) RBE4 cells were maintained 5 days in diﬀerentiation medium
(F10/MEM, 2.5% FCS, hydrocortisone 14μM, Hepes 10mM, bFGF 1μg/mL). RBE4 cells were stimulated for 45min with Aβ1-42 (3μM).
Subcellularfractionswereobtainedusingacellfractionationkit(Biorad)accordingtothemanufacturerinstruction.ThepresenceofTXNIP,
RAGE, VE-cadherin, and histone H3 were analyzed by western blotting. (b) RBE4 cells were maintained as described in (a) and stimulated
for 45min with Aβ1-42 (3μM). Cells were ﬁxed in PBS containing 4% PFA and permeabilized 10min in PBS 0.1% Triton X-100. Cells were
maintained 1h in blocking solution (PBS 3% BSA) at room temperature and then incubated over/night at 4◦C with a rabbit anti-TXNIP
polyclonal antibody (Invitrogen) and a mouse anti-VEcadherin monoclonal antibody (Santa Cruz biotechnology) in blocking solution.
Cells were washed 3 times for 15min with PBS and incubated with the appropriate secondary antibody. Nuclei were stained with Hoecst.
Immunoﬂuorescence was analyzed by a confocal microscopy (Zeiss). These data are representative of 3 independent experiments.International Journal of Alzheimer’s Disease 9
showed that patient, who had received the low dose of
PF-04494700 showed an improved ADAS-cog score after
18 months, when compared to the placebo group, even if
they were taken oﬀ the treatment with PF-04494700 after
12 months. Thus, Galasko suggests that it was an error to
stop the clinical trial, at least with the low-dose group. The
researcher also reported that the high-dose group completely
recovered with the ADAS-cog score after 18 month; thus,
the toxic eﬀect was reversible. He did not explain the
reason of the toxicity induced by the higher dose of PF-
04494700. As outlined in the present, RAGE participates in
neurite outgrowth, and RAGE is highly expressed in brain
neurons during the development. The higher dose of PF-
04494700 might thus block or at least interfere with the
yet mot clearly deﬁned physiological functions of RAGE,
thereby aﬀecting neurogenesis. On the contrary, the lower
dose of PF-04494700, which was beneﬁcial in the long time,
suggests that the inhibition of chronic RAGE activation
can ameliorate AD progression and imply follow-up studies
using low dose of PF-04494700 to inhibit RAGE-induced
chronic neurovascular dysfunction.
8. Conclusions andHypothesis
Herein, we summarize all studies indicating that RAGE
participates in sporadic AD progression by activating several
pathways in diﬀerent cell types, particularly BBB, glia, and
neurons (Figure 4) .T h e s ep a t h w a y sc o n v e r g ea n du l t i m a t e l y
lead to synaptic dysfunction and neurodegeneration. We also
report ongoing studies demonstrating that RAGE partici-
pates in AD progression by inducing TXNIP expression. We
previously demonstrated that RAGE-TXNIP axis is induced
in diﬀerent cell types and promotes inﬂammation [26, 27].
Moreover, we have shown that enhanced TXNIP expression
indiabetesultimatelyleadstoneurodegeneration[30].Inthe
present paper, we show that RAGE-TXNIP axis is induced
in brain endothelial cells. In addition, we demonstrate
for the ﬁrst time that TXNIP is early overexpressed in
the hippocampus of an AD mouse model. Several studies
suggest that brain insulin resistance is implicated in AD
progression. However, the molecular mechanisms leading to
braininsulinresistanceinADarestillunknown.Ourdataare
suggesting that RAGE may induce brain insulin resistance by
enhancing TXNIP expression. Only one study demonstrated
that RAGE triggering induces insulin resistance and impairs
g l u c o s eu p t a k ei ns k e l e t a lm u s c l e[ 102]. Induction of RAGE-
TXNIP axis in AD brain can further demonstrate the
role of RAGE in amplifying age-induced oxidative stress.
Indeed, TXNIP induces oxidative stress. The analysis of Aβ-
induced TXNIP expression in glial and neuronal cells is
under investigation. However, we and other demonstrated
that TXNIP is necessary to induce IL-1β expression [27,
103] and to promote neurodegeneration [30, 93]. Thus, we
hypothesize that RAGE-TXNIP axis participates in AD pro-
gression by activating a concerted action of oxidative stress,
inﬂammation,vasculardysfunction,andneurodegeneration.
We also hypothesize that pharmacological treatments
aimed to inhibit chronic RAGE activation will be beneﬁ-
cial in blocking neurovascular dysfunction in AD, thereby
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Figure 4: PF-04494700, an inhibitor of RAGE, can ameliorate
sporadic AD and promote neuroprotection by blocking RAGE
activation in various cell type. Aging-induced oxidative stress leads
to the formation of AGEs, which activate RAGE together with
Aβ in various cell type. Triggering of RAGE at the BBB leads
to TXNIP expression and subsequent inﬂammation, BBB leakage,
and monocytes inﬁltration. Moreover, RAGE triggering induces a
positive feedback loop enhancing RAGE expression, resulting in
enhanced transport of Aβ from the blood to the brain. RAGE
activation in glial cells promotes proinﬂammatory gene expression,
which enhanced Aβ production inside the brain and neurotoxicity.
RAGE triggering in neuronal cells induces oxidative stress and the
production of M-CSF, leading to inﬂammation. Thus, activation
of RAGE in diﬀerent cell types orchestrates the neuroinﬂamma-
tory processes that ultimately lead to neurodegeneration. Thus,
treatments aimed to inhibit chronic RAGE activation will confer a
neuroprotective eﬀect by blocking RAGE-mediated neurovascular
dysfunction.
conferring a neuroprotective eﬀect by restoring the physi-
ological function of RAGE and TXNIP that are implicated
in neuronal diﬀerentiation and repair. Thus, a prolonged
treatment with a low dose of PF-04494700 might block the
eﬀects induced by RAGE chronic activation and ameliorate
AD progression.
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